Image of a stylised green COVID-19 virus


The PREPARE project aims to understand the risk COVID-19 poses for patients with blood cancers using information from participants from the RUDY study. The first wave of the project will focus on myeloma patients who have joined the RUDY study. The information collected will help healthcare professionals and patients work together to balance the potential risk of COVID-19 and blood cancer management appropriately.

We want to know:

  • Are blood cancer patients at greater risk of severe COVID-19 disease ?
  • Do blood cancer patient mount an immune response to COVID-19 and is this response sustained over time?
  • Do patients with blood cancer mount immunity with COVID-19 vaccination?
  • Should blood cancer treatment be altered to optimise COVID-19 vaccine immunity?
Image of a stylised pink COVID-19 virus


To find out more:

  1. Go to and click on "Find out more"
  2. Read the patient information sheet in the "Library"
  3. If you want to take part then you can do this online by clicking on the green Join us now button.
  4. Follow the steps and you will soon be able to share your data with researchers focused on improving care for patients with myeloma.

If there are any questions you can’t find answers to then please send us an email at or call us on 07775 541615 / 01865 223407 and we will get back to you

Image of a stylised purple COVID-19 virus


Dr Karthik Ramasamy together with colleagues at Oxford University Hospital , working in close collaboration with the RUDY study team at University of Oxford ( Prof Udo Oppermann, Dr Kassim Javaid and Dr Ross Sadler ).

We also work with collaborators around the UK on this project: Prof Gordon Cook, Leeds; Dr Stella Bowcock, Kings College Hospital; Dr Chara Kyriakou, UCL; Dr Sally Moore, Bath/Oxford; Prof Mark Drayson, Birmingham; Dr Dean Smith, Nottingham; Professor Supratik Basu and his Colleagues at West Midlands Research Consortium (WMRC).

Image of a stylised black COVID-19 virus


The RUDY research platform has been designed for individual with rare conditions, including myeloma. RUDY platform includes rare blood disorders, and has already recruited over 500 myeloma (blood cancer) patients in the 2 years it has been open ( PREPARE project will use data from participants in the RUDY study.